Health Care & Life Sciences » Biotechnology | Argos Therapeutics Inc.

Argos Therapeutics Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
Sales/Revenue
4,421.70
1,974.00
518.30
945.50
1,899.40
SG&A Expense
28,042.00
53,532.20
72,385.40
51,558.20
32,871.40
EBIT
24,231.80
52,124.30
-
51,565.10
31,939.90
Unusual Expense
355.40
200.00
-
266.20
10,171.30
Non Operating Income/Expense
47.60
75.30
2.80
11.90
2,777.40
Interest Expense
4.70
1,123.60
2,263.60
1,774.70
1,308.20
Pretax Income
23,921.60
53,305.90
74,788.50
53,028.10
40,577.50
Consolidated Net Income
23,921.60
53,305.90
74,788.50
53,028.10
40,577.50
Net Income
23,921.60
53,305.90
74,788.50
53,028.10
40,577.50
Net Income After Extraordinaries
23,921.60
53,305.90
74,788.50
53,028.10
40,577.50
Net Income Available to Common
33,874.70
54,169.20
74,788.50
53,028.10
40,577.50
EPS (Basic)
491.23
62.40
73.20
33.20
13.45
Basic Shares Outstanding
69.00
868.40
1,022.90
1,600.30
3,017.40
EPS (Diluted)
491.23
62.38
73.12
33.14
13.45
Diluted Shares Outstanding
69.00
868.40
1,022.90
1,600.30
3,017.40
EBITDA
23,620.40
51,558.10
71,867.10
50,612.70
30,972.00
Non-Operating Interest Income
7.20
66.60
25.40
57.30
64.50
Preferred Dividends
9,953.10
863.20
-
-
-

About Argos Therapeutics

View Profile
Address
4233 Technology Drive
Durham North Carolina 27704
United States
Employees -
Website http://www.argostherapeutics.com
Updated 09/14/2018
Argos Therapeutics, Inc. is a biopharmaceutical company, which engages in development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its proprietary technology platform called Arcelis. Its product candidates include AGS-003 for the treatment of metastatic renal cell carcinoma, and other cancers; and AGS-004 for the treatment of human immunodeficiency virus. The company was founded by Ralph Steinman on May 8, 1997 and is headquartered in Durham, NC.